iMatrix-511

Propagation of embryonic stem (ES) cells or induced pluripotent stem (iPS) cells requires a culture substrate that retains pluripotency, a stable karyotype, and expression of pluripotency markers. iMatrix-511 is a recombinant laminin-511 E8 fragment product that can be used as an ES or iPS cell-culture substrate. Propagation of embryonic stem (ES) cells or induced pluripotent stem (iPS) cells requires a culture substrate that retains pluripotency, a stable karyotype, and expression of pluripotency markers. iMatrix-511 is a recombinant laminin-511 E8 fragment product that can be used as an ES or iPS cell-culture substrate. These recombinant laminin-511 E8 fragments permit maintenance of human ES and iPS cells in xeno-free culture conditions and provide greater adhesive properties than either full-length laminin, vitronectin, or undefined basement membrane reagents such as Matrigel. The iMatrix-511 cell-culture reagent allows stem cell culture in the absence of mouse feeder cells. Recombinant laminin-511 E8 fragments are truncated, functional forms of laminin composed of the C-terminal regions of the alpha, beta, and gamma chains. Laminin-511 E8 (150 kDa) retains the full capability for binding to alpha 6 beta 1 integrin. Based on research performed at Kyoto University and Osaka University, recombinant laminin-511 E8 fragments are available as iMatrix-511. This product is available through an agreement between Takara Bio Inc. and Nippi, Inc. Laminin-511 is well known to bind to integrin α6ß1, which is located on the cell surface. iMatrix-511 is a recombinant fragment of laminin-511 which acts as a substrate for stem cell culture media for ESCs and iPSCs. iMatrix-511 is chemically defined, animal-free, and xeno-free. Our products are to be used for Research Use Only. They may not be used for any other purpose, including, but not limited to, use in humans, therapeutic or diagnostic use, or commercial use of any kind. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without our prior written approval.